血清SRGN、sCD146水平与老年乳腺癌患者临床病理特征及预后的关系  

Relationship between serum SRGN,sCD146 levels and clinicopathological characteristics and prognosis in elderly patients with breast cancer

作　　者：常培江 崔立春 冷宁 周明玉 万诗扬 CHANG Peijiang;CUI Lichun;LENG Ning;ZHOU Mingyu;WAN Shiyang(Department of Radiotherapy,Qingdao Jiaozhou Central Hospital(Qingdao People's Hospital Group Jiaozhou),Qingdao,Shandong 266300,China;Department of Hepatobiliary and Breast Surgery,Qingdao Jiaozhou Central Hospital(Qingdao People's Hospital Group Jiaozhou),Qingdao,Shandong 266300,China)

机构地区：[1]青岛市胶州中心医院(青岛市人民医院集团胶州)放疗科,山东青岛266300 [2]青岛市胶州中心医院(青岛市人民医院集团胶州)肝胆甲乳外科,山东青岛266300

出　　处：《国际检验医学杂志》2025年第7期817-822,共6页International Journal of Laboratory Medicine

基　　金：山东省医药卫生科技发展计划项目(20204010117)。

摘　　要：目的 探究老年乳腺癌(BC)患者血清糖蛋白丝甘蛋白聚糖(SRGN)、分泌型CD146(sCD146)水平与临床病理特征及预后的相关性。方法 回顾性选取2019年4月至2021年4月该院诊治的128例老年BC患者作为BC组,另选取同期70例老年健康女性作为对照组。分析BC组和对照组,以及BC组不同临床病理特征患者血清SRGN、sCD146水平差异。采用Kaplan-Meier曲线和COX回归分析血清SRGN、sCD146对老年BC患者预后的影响。采用受试者工作特征曲线分析血清SRGN、sCD146对老年BC患者预后的预测价值。结果 BC组血清SRGN、sCD146水平分别为(13.17±3.35)μg/L、(118.23±20.51)ng/L,高于对照组的(2.52±0.41)μg/L、(20.03±4.16)ng/L(t=26.460、39.572,均P<0.001)。相比于TNM分期Ⅰ~Ⅱ期、组织学分级Ⅰ~Ⅱ级老年BC患者,TNM分期Ⅲ期、组织学分级Ⅲ级老年BC患者血清SRGN、sCD146水平更高(P<0.05)。SRGN高表达组和低表达组3年无进展生存率分别为66.13%(41/62)、92.42%(61/66),SRGN高表达组3年无进展生存率低于低表达组(Log Rank χ^(2)=14.180,P<0.001)。sCD146高表达组和低表达组3年无进展生存率分别为68.85%(42/61)、89.55%(60/67),sCD146高表达组3年无进展生存率低于低表达组(Log Rank χ^(2)=8.614,P=0.003)。TNM分期Ⅲ期、组织学分级Ⅲ级、血清SRGN、sCD146是老年BC患者预后不良的危险因素(P<0.05)。血清SRGN、sCD146联合预测老年BC患者预后的曲线下面积(AUC)为0.850,大于SRGN(AUC=0.798)、sCD146(AUC=0.771)单项预测(Z=2.057、2.217,P=0.042、0.029)。结论 老年BC患者血清SRGN、sCD146水平升高,二者均参与BC的疾病进展,两项联合检测对老年BC患者预后具有较高的预测价值。Objective To explore the relationship between serum levels of glycoprotein fibroglycan(SRGN) and secretory CD146(sCD146) and clinicopathological characteristics and prognosis in elderly patients with breast cancer(BC).Methods A total of 128 elderly BC patients treated in the hospital from April 2019 to April 2021 were retrospectively selected as the BC group,and another 70 healthy elderly women were selected as the control group.The serum SRGN and sCD146 levels in BC group and control group,and patients with different clinical and pathological characteristics in BC group were compared.Kaplan-Meier curve and COX regression were used to analyze the effect of serum levels of SRGN and sCD146 on the prognosis of elderly BC patients.Receiver operating characteristic curve was used to analyze the predictive value of serum levels of SRGN and sCD146 for the prognosis of elderly BC patients.Results The levels of serum SRGN and sCD146 were(13.17±3.35) μg/L,(118.23±20.51) ng/L in the BC group,which were higher than(2.52±0.41) μg/L,(20.03±4.16) ng/L in the control group(t=26.460,39.572,both P<0.001).Compared with elderly BC patients with TNM stage Ⅰ-Ⅱ and histological grade Ⅰ-Ⅱ,serum SRGN and sCD146 levels in elderly BC patients with TNM stage Ⅲ and histological grade Ⅲ were higher(P<0.05).The 3-year progression free survival rates in SRGN high and low expression groups were 66.13%(41/62) and 92.42%(61/66),respectively,and the 3-year progression free survival rate in SRGN high expression group was lower than that in SRGN low expression group(Log Rank χ^(2)=14.180,P<0.001).The 3-year progression free survival rates in sCD146 high and low expression groups were 68.85%(42/61) and 89.55%(60/67),respectively,and the 3-year progression free survival rate in sCD146 high expression group was lower than that in sCD146 low expression group(Log Rank χ^(2)=8.614,P=0.003).TNM stage Ⅲ,histological grade Ⅲ,serum SRGN and sCD146 were risk factors for the poor prognosis of elderly BC patients.The area under the curve(A

关 键 词：乳腺癌 糖蛋白丝甘蛋白聚糖 分泌型CD146 预后 

分 类 号：R737.9[医药卫生—肿瘤]